Huabang pharmaceutical psoriasis Class 1.5 new drug tazarotene betamethasone cream obtained the production approval

According to the information on the website of CFDA on April 13, the status of tazarotene betamethasone cream, a 1.5 dermatological drug of Huabang pharmaceutical, was changed to "certificate preparation completed - approval document issued in Chongqing" This means that the product is about to be approved for marketing The company said that the R & D process of the drug was relatively smooth, but no approval has yet been received "The company will issue an announcement as soon as it receives the approval." Tazarotene betamethasone cream is a compound preparation of tazarotene and betamethasone, which is mainly used for the treatment of psoriasis It is developed by Huabang Yingtai, and has not been declared by other manufacturers After being approved, it will become an exclusive product The market is expected to reach 100-200 million It is worth mentioning that the tazarotene betamethasone cream of Huabang Yingtai has been listed as one of the 76 major special varieties published by CDE As early as 2012, the product was included in the list of 100 key products of Chongqing pharmaceutical industry, with a total investment of 8 billion yuan Huabang Yingtai has focused on the development of Dermatology prescription drug market for many years, cooperated with Parkson pharmaceutical to expand new sales channels such as e-commerce, and is expected to open up a broader sales space According to the annual report, the company's operating revenue in 2014 was 4.867 billion yuan, up 9.0% year on year; the net profit attributable to the parent company was 429 million yuan, up 41.8% year on year "Tazarotene betamethasone cream" is a new compound drug for the treatment of psoriasis In the compound preparation, "betamethasone dipropionate" and "tazarotene" are two effective components for the treatment of psoriasis They play an anti psoriasis role through different mechanisms "Betamethasone dipropionate" can accelerate the initial response time to take effect in the early stage of treatment, "tazarotene" can prolong the duration of the effect and reduce the possibility of recurrence, the drug combination has been granted a patent for invention During the research and development of the drug, more than 1000 subjects from 13 clinical units, including Dermatology Hospital of Chinese Academy of Medical Sciences, confirmed that the "tazarotene betamethasone cream" for the treatment of psoriasis vulgaris has rapid onset, clear efficacy, low recurrence rate, high safety, and obvious clinical application advantages The successful development of "tazarotene betamethasone cream" has provided a new drug for the treatment of psoriasis and brought more hope for cure to the majority of patients After being put into operation, the annual new output will reach more than 70 million yuan